Literature DB >> 26497165

Feasibility study of the Fab fragment of a monoclonal antibody against tissue factor as a diagnostic tool.

Ryo Tsumura1, Ryuta Sato1, Fumiaki Furuya1, Yoshikatsu Koga1, Yoshiyuki Yamamoto2, Yuki Fujiwara1, Masahiro Yasunaga1, Yasuhiro Matsumura1.   

Abstract

Tissue factor (TF) is expressed strongly in various types of cancer, especially cancers that are often refractory to treatment, such as pancreatic cancer. In this study, we compared the differences in the biophysical and pharmacological properties of whole IgG and the Fab fragment of anti-human TF monoclonal antibody (1849 antibodies), in order to determine their suitability for application in the diagnosis and treatment of cancers. In the biophysical examination, we investigated the characteristics of 1849-whole IgG and 1849-Fab by SPR sensing and confocal fluorescence microscopy analysis using recombinant human TF antigen and TF-overexpressing human pancreatic cancer cell line, BxPC3, respectively. After conjugation with Alexa-Flour-647, in vivo imaging was conducted in mice bearing BxPC3 xenograft tumors. Furthermore, the distribution of the conjugates in tumors and major organs was evaluated by ex vivo study. The in vitro experiments showed that 1849 antibodies had high affinity against TF antigen. In addition, 1849-Fab showed a faster dissociation rate from the antigen than 1849-whole IgG. In mice, 1849-Fab-Alexa-Flour-647 showed rapid renal clearance and faster tumor accumulation, achieving a high contrast signal over nearby normal tissues in the early phase and enhanced tumor penetration after administration. On the other hand, 1849-whole IgG-Alexa-Flour-647 showed slow clearance from the blood and sustained high tumor accumulation. These results suggest that 1849-Fab may be a useful tool for pancreatic cancer diagnosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26497165     DOI: 10.3892/ijo.2015.3210

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

1.  Inhibition of the Classical Pathway of Complement Activation Impairs Bacterial Clearance during Enterococcus faecalis Infection.

Authors:  Youssif M Ali; Ramadan Hassan; Eman M Rabie Shehab El-Din; Abdelaziz Elgaml
Journal:  Infect Immun       Date:  2021-04-16       Impact factor: 3.441

2.  Nanobody Conjugates for Targeted Cancer Therapy and Imaging.

Authors:  Wei Kang; Chuanfeng Ding; Danni Zheng; Xiao Ma; Lun Yi; Xinyi Tong; Chuang Wu; Chuang Xue; Yongsheng Yu; Qian Zhou
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

3.  Molecular imaging using an anti-human tissue factor monoclonal antibody in an orthotopic glioma xenograft model.

Authors:  Hiroki Takashima; Atsushi B Tsuji; Tsuneo Saga; Masahiro Yasunaga; Yoshikatsu Koga; Jun-Ichiro Kuroda; Shigetoshi Yano; Jun-Ichi Kuratsu; Yasuhiro Matsumura
Journal:  Sci Rep       Date:  2017-09-26       Impact factor: 4.379

4.  Evaluation of the antitumor mechanism of antibody-drug conjugates against tissue factor in stroma-rich allograft models.

Authors:  Ryo Tsumura; Shino Manabe; Hiroki Takashima; Yoshikatsu Koga; Masahiro Yasunaga; Yasuhiro Matsumura
Journal:  Cancer Sci       Date:  2019-08-29       Impact factor: 6.716

5.  Radioimmunotherapy with an 211 At-labeled anti-tissue factor antibody protected by sodium ascorbate.

Authors:  Hiroki Takashima; Yoshikatsu Koga; Shino Manabe; Kazunobu Ohnuki; Ryo Tsumura; Takahiro Anzai; Nozomi Iwata; Yang Wang; Takuya Yokokita; Yukiko Komori; Daiki Mori; Sachiko Usuda; Hiromitsu Haba; Hirofumi Fujii; Yasuhiro Matsumura; Masahiro Yasunaga
Journal:  Cancer Sci       Date:  2021-03-30       Impact factor: 6.716

6.  The natural sulfoglycolipid derivative SQAP improves the therapeutic efficacy of tissue factor-targeted radioimmunotherapy in the stroma-rich pancreatic cancer model BxPC-3.

Authors:  Yoichi Takakusagi; Aya Sugyo; Atsushi B Tsuji; Hitomi Sudo; Masahiro Yasunaga; Yasuhiro Matsumura; Fumio Sugawara; Kengo Sakaguchi; Tatsuya Higashi
Journal:  Transl Oncol       Date:  2021-11-25       Impact factor: 4.243

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.